Human Vaccines & Immunotherapeutics最新文献_第6页

Nanovaccine loaded with seno-antigen target senescent cells to improve metabolic disorders of adipose tissue and cardiac dysfunction.

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-03-15 DOI: 10.1080/21645515.2025.2479229

Kexin Zhang, Qiliang Yin, Yucen Ma, Mengyu Cao, Lingwei Li, Xinliang Jin, Jiyan Leng

{"title":"Nanovaccine loaded with seno-antigen target senescent cells to improve metabolic disorders of adipose tissue and cardiac dysfunction.","authors":"Kexin Zhang, Qiliang Yin, Yucen Ma, Mengyu Cao, Lingwei Li, Xinliang Jin, Jiyan Leng","doi":"10.1080/21645515.2025.2479229","DOIUrl":"10.1080/21645515.2025.2479229","url":null,"abstract":"The buildup of senescent cells exacerbates metabolic disorders in adipose tissue and contributes to aging-related cardiac dysfunction. Targeted clearance of senescent cells can markedly ameliorate these aging-related diseases. Here, we developed a novel nanovaccine (GK-NaV) loaded with seno-antigen that is self-assembled from the fusion of cationic protein (K36) and seno-antigen peptide (Gpnmb). The GK-NaV could be highly engulfed by bone marrow-derived dendritic cells (BMDCs) and efficiently present antigens on the cellular surface, thereby promoting DCs maturation and activation of CD8+T cells in vitro. Following subcutaneous immunization, GK-NaV not only exhibited a noticeable antigen depot effect but also markedly activated specific cellular immune responses, enhancing the immunoreactivity and cytotoxic effects of CD8+T cells. Consequently, the targeted anti-aging immunity triggered by GK-NaV demonstrated the ability to selectively eliminate senescent adipocytes and cardiomyocytes in high-fat diet (HFD)-induced progeroid mice, leading to a significant improvement in age-related metabolic disorders in adipose tissue and cardiac dysfunction. Hence, our findings indicate that immunization with GK-NaV targeting seno-antigens may represent a promising strategy for novel senolytic therapies.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2479229"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11916409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhanced passive safety surveillance of standard-dose and high-dose influenza vaccines in Finland and Germany 2023-24 season.

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-03-18 DOI: 10.1080/21645515.2025.2475616

Marina Amaral de Avila Machado, Sophie Gallo, Alexander Goldstein, Parth Vachhani, Reddappa Maniganahally Byrareddy, Anu Kantele, Hanna Välimaa, Jörg Schelling

{"title":"Enhanced passive safety surveillance of standard-dose and high-dose influenza vaccines in Finland and Germany 2023-24 season.","authors":"Marina Amaral de Avila Machado, Sophie Gallo, Alexander Goldstein, Parth Vachhani, Reddappa Maniganahally Byrareddy, Anu Kantele, Hanna Välimaa, Jörg Schelling","doi":"10.1080/21645515.2025.2475616","DOIUrl":"https://doi.org/10.1080/21645515.2025.2475616","url":null,"abstract":"Enhanced Passive Safety Surveillance was used to detect safety signals before the peak period of immunization with quadrivalent inactivated influenza vaccines (IIV4) in Finland (standard dose [SD]) and Germany (high dose [HD]) in the 2023-24 season. The primary objective was to evaluate adverse drug reactions (ADRs) occurring ≤7 days following IIV4 vaccination. Enrolled participants were vaccinated in routine clinical care settings and encouraged to report ADRs. Exposure data and ADR reports were collected in a near real-time manner using an electronic system. Vaccinee reporting rate (RR) with 95% confidence interval (CI) was calculated as the number of vaccinees reporting ≥ 1 ADR divided by total number of vaccinees. In Finland for SD-IIV4, among 1,003 vaccinees aged ≥ 6 months, 81 reported a total of 192 suspected ADRs occurring ≤ 7 days following vaccination (vaccinee RR 8.08%; 95% CI 6.46, 9.94). In Germany for HD-IIV4, among 1,075 vaccinees aged ≥ 60 years, 15 reported 46 ADRs that occurred in ≤ 7 days of vaccination (vaccinee RR 1.40%; 95% CI 0.78, 2.29). No safety signal was detected during this surveillance. The 2023-24 season surveillance did not suggest any clinically significant changes in safety profile compared with previously reported safety data for SD-IIV4 and HD-IIV4.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2475616"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies. 9价人乳头瘤病毒疫苗的免疫原性：来自5个3期研究的事后分析

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-01-22 DOI: 10.1080/21645515.2024.2425146

Anna R Giuliano, Joel M Palefsky, Stephen E Goldstone, Jacob Bornstein, Ilse De Coster, Ana María Guevara, Ole Mogensen, Andrea Schilling, Pierre Van Damme, Corinne Vandermeulen, Misoo C Ellison, Susan Kaplan, Jianxin Lin, Rachael Bonawitz, Alain Luxembourg

{"title":"Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies.","authors":"Anna R Giuliano, Joel M Palefsky, Stephen E Goldstone, Jacob Bornstein, Ilse De Coster, Ana María Guevara, Ole Mogensen, Andrea Schilling, Pierre Van Damme, Corinne Vandermeulen, Misoo C Ellison, Susan Kaplan, Jianxin Lin, Rachael Bonawitz, Alain Luxembourg","doi":"10.1080/21645515.2024.2425146","DOIUrl":"https://doi.org/10.1080/21645515.2024.2425146","url":null,"abstract":"Post hoc analyses of 9-valent human papillomavirus (9vHPV) vaccine immunogenicity were conducted in five Phase 3 studies that enrolled males. Month 7 antibody geometric mean titers (GMTs) after three 9vHPV vaccine doses were analyzed in 10,024 males/females aged 16-26 years from studies 001 (NCT00543543), 002 (NCT00943722), 003 (NCT01651949), and 020 (NCT02114385). Covariates considered were age, gender, sexual orientation, region of residence, and race. GMTs among 2599 males/females aged 9-15 years (studies 002 and 010 [NCT01984697]) were assessed 6 months after one, two, and three 9vHPV vaccine doses. 9vHPV vaccine immunogenicity was robust across populations. Month 7 GMTs were generally higher in participants aged 16-21 versus 22-26 years. Region and race minimally impacted immunogenicity. Adjusted integrated analysis showed lower immunogenicity in men who have sex with men (MSM) versus heterosexual men (HM) for nine HPV types, and higher immunogenicity in HM versus females for seven HPV types. Among 9-15-year-olds, trends toward higher GMTs in males versus females post-Dose 3, similar GMTs post-Dose 2, and lower post-Dose 1 were observed. In conclusion, 9vHPV vaccine immunogenicity was robust in males aged 16-26 years across a range of baseline characteristics. GMT ratios for males versus females aged 9-15 years tended to increase with more doses.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2425146"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Closer adult child-parent relations the stronger the vaccine hesitancy: A cross-sectional study of adult Children's attitudes toward pneumococcal vaccination of elderly parents and its determinants in Guangzhou, China. 成人亲子关系越密切，疫苗犹豫越强：中国广州成年子女对老年父母肺炎球菌疫苗接种态度及其决定因素的横断面研究

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-01-05 DOI: 10.1080/21645515.2024.2440959

Qiqi Wu, Haiyuan Zhu, Runquan Zhang, Cuizhi Li, Qin Xiao, Yuqing Jin, Xiaofeng Liang, Xiongfei Chen, Xiaomei Dong

{"title":"Closer adult child-parent relations the stronger the vaccine hesitancy: A cross-sectional study of adult Children's attitudes toward pneumococcal vaccination of elderly parents and its determinants in Guangzhou, China.","authors":"Qiqi Wu, Haiyuan Zhu, Runquan Zhang, Cuizhi Li, Qin Xiao, Yuqing Jin, Xiaofeng Liang, Xiongfei Chen, Xiaomei Dong","doi":"10.1080/21645515.2024.2440959","DOIUrl":"https://doi.org/10.1080/21645515.2024.2440959","url":null,"abstract":"Pneumococcal disease (PD) has a serious effect on older people aged 60 years and above. However, pneumococcal vaccination rates for older people in China remain low. This study aimed to explore adult children's perspectives on the vaccination of their parents and to examine the determinants of vaccine hesitancy. In October 2022, a cross-sectional survey was conducted in Guangzhou, China. The questionnaire assesses data on the sociodemographic characteristics of adult children and their parents, health beliefs about vaccination, and variables measuring adult child-parent relationships. Adult child-parent relationships types were identified by Latent Class Analysis (LCA). Binary logistic regression was employed to examine the factors associated with vaccine hesitancy. A total of 1,597 respondents were enrolled in the study, and 59.8% of the adult children expressed hesitancy about vaccinating their elderly parents. The LCA model identified three distinct types of adult child-parent relations: detached, intimate but distant, and tight-knit. Binary logistic regression analyses revealed that respondents with intimate but distant (OR = 3.04) and tight-knit (OR = 3.01) adult child - parent relationships, high literacy (OR = 2.63), and high perceived barriers of vaccine (OR = 1.18) were more likely to be hesitant. Conversely, those with high income (OR = 0.35) and parents with difficulties in activities of daily living (OR = 0.44) were less likely to exhibit vaccine hesitancy. Close adult child-parent relations were positively associated with vaccine hesitancy. Health education related to the vaccination of older persons should be extended to adult children.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2440959"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Socioeconomic disparities in childhood vaccine hesitancy among parents in China: The mediating role of social support and health literacy. 中国父母儿童疫苗犹豫的社会经济差异：社会支持和卫生素养的中介作用

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-01-08 DOI: 10.1080/21645515.2024.2444008

Xuelin Yao, Mao Fu, Jin Peng, Da Feng, Yue Ma, Yifan Wu, Liuxin Feng, Yu Fang, Minghuan Jiang

{"title":"Socioeconomic disparities in childhood vaccine hesitancy among parents in China: The mediating role of social support and health literacy.","authors":"Xuelin Yao, Mao Fu, Jin Peng, Da Feng, Yue Ma, Yifan Wu, Liuxin Feng, Yu Fang, Minghuan Jiang","doi":"10.1080/21645515.2024.2444008","DOIUrl":"10.1080/21645515.2024.2444008","url":null,"abstract":"Parental vaccine hesitancy is a major obstacle to childhood vaccination. We examined parental socioeconomic status (SES) disparities in vaccine hesitancy, and the potential mediating roles of perceived social support and health literacy. A questionnaire survey was given to parents with children aged below 6 years from six provinces in China. SES was examined by educational attainment, annual household income, and a subjective measure of SES (using a scale of 1-10). Linear regression was applied to assess the association between SES and vaccine hesitancy. Bootstrapping mediation analysis was performed with 5,000 samples bootstrapped. A total of 1,638 parents were included. Using annual household income > 200,000 Chinese yuan (CNY) as a reference, parents with lower household income (CNY 100,001-150,000) experienced higher vaccine hesitancy. Educational attainment was not associated with vaccine hesitancy. Subjective SES had a U-shaped relationship with vaccine hesitancy. Perceived social support and health literacy independently and sequentially mediated the effects of subjective SES (indirect effect: -0.240) and annual household income (indirect effect: 1.250 for ≤ CNY 100,000 and 0.759 for CNY 100,001-150,000) on vaccine hesitancy. Socioeconomic disparities influenced parental vaccine hesitancy in China, which were mediated by perceptions of social support and health literacy.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2444008"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142957513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunogenicity and safety of HepE Hecolin® in chronic hepatitis B patients at clinically stable stage: An open-label study in China. HepE Hecolin®在临床稳定期慢性乙型肝炎患者中的免疫原性和安全性：中国的一项开放标签研究

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-01-10 DOI: 10.1080/21645515.2024.2448882

Li Zhang, Qiufen Zhang, Jiaye Liu, Wenlong Wu, Zechun Jiang, Bingyu Yan, Qingfan Cao, Haidong Liu, Huirong Pan, Jingjing Lv, Yi Feng, Fujie Xu, Shoujie Huang, Aiqiang Xu

{"title":"Immunogenicity and safety of HepE Hecolin® in chronic hepatitis B patients at clinically stable stage: An open-label study in China.","authors":"Li Zhang, Qiufen Zhang, Jiaye Liu, Wenlong Wu, Zechun Jiang, Bingyu Yan, Qingfan Cao, Haidong Liu, Huirong Pan, Jingjing Lv, Yi Feng, Fujie Xu, Shoujie Huang, Aiqiang Xu","doi":"10.1080/21645515.2024.2448882","DOIUrl":"10.1080/21645515.2024.2448882","url":null,"abstract":"Acute hepatitis E infection could induce severe outcomes among chronic hepatitis B (CHB) patients. Between 2016 and 2017, an open-label study was conducted to evaluate the immunogenicity and safety of hepatitis E vaccine (HepE) in CHB patients, using healthy adults as parallel controls in China. Eligible participants who were aged ≥30 y were enrolled in the study. The CHB group included participants who had ever developed symptoms of hepatitis because of CHB but was currently at a clinically stable stage, which was defined as ALT ≤ 1.5 times of upper limit of the normal range (ULN) in this study. The control group included healthy adults who had hepatitis B surface antigen (HBsAg) negative. HepE was administered for 0, 1, 6 months for all participants. At 1 month after the third-dose vaccination (month 7), the seroconversion rates of anti-HEV IgG were >97% in both groups. The geometric mean concentration (GMC) of anti-HEV IgG in the CHB group was non-inferior to the healthy adult group (0.69 WU/mL, 95% CI 0.55-0.85). The proportion of the participants with adverse events ≥ grade 3 was similar in both groups (p = .99), and no vaccine-associated severe adverse events were identified. Changes in the liver function indicators were not of clinical significance. The HepE was highly immunogenic and well tolerated among clinically stable CHB patients and healthy adults.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2448882"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hotspots evolution and frontiers of immunotherapy for the treatment of acute myeloid leukemia: A bibliometric analysis. 急性髓性白血病免疫治疗的热点、发展和前沿：文献计量学分析。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-01-17 DOI: 10.1080/21645515.2024.2448888

Nana Zhe, Qiang Li, Nanqu Huang, Hang Li, Hongyun Chen, Pinwei Zhu

{"title":"Hotspots evolution and frontiers of immunotherapy for the treatment of acute myeloid leukemia: A bibliometric analysis.","authors":"Nana Zhe, Qiang Li, Nanqu Huang, Hang Li, Hongyun Chen, Pinwei Zhu","doi":"10.1080/21645515.2024.2448888","DOIUrl":"https://doi.org/10.1080/21645515.2024.2448888","url":null,"abstract":"Given the growing significance of immunotherapy in addressing the limitations of conventional acute myeloid leukemia (AML) treatments, this study aimed to elucidate the hotspot evolution and frontiers of immunotherapy in AML using bibliometric analysis. With a strict retrieval strategy applied in the Web of Science Core Collection, 2411 publications were obtained and exported. The temporal and geographical distributions of these publications and the countries, institutions, journals, and authors who contributed to the field were investigated. An in-depth content analysis was performed. The United States had various research institutions dedicated to AML immunotherapy. Frontiers in Immunology had the highest number of publications, but Blood had the highest H-index. Marion Subklewe was the most productive author. The current research hotspots of AML immunotherapy included chimeric antigen receptor-T-cell therapy, antibody-based immunotherapies, immune checkpoint blockade, and combination therapy, highlighting the key aspects of immunotherapy for AML treatment and providing comprehensive insights into the research status and advances in this field. Novel immunotherapies combined with chemotherapy may become the primary focus of AML treatment.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2448888"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Australian preferences for influenza vaccine attributes and cost: A discrete choice experiment. 澳大利亚人对流感疫苗属性和成本的偏好：一个离散选择实验。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2024-12-21 DOI: 10.1080/21645515.2024.2440164

Simon Fifer, Lili Toh, Daniel Yu, Katherine Young, Jason Menche

{"title":"Australian preferences for influenza vaccine attributes and cost: A discrete choice experiment.","authors":"Simon Fifer, Lili Toh, Daniel Yu, Katherine Young, Jason Menche","doi":"10.1080/21645515.2024.2440164","DOIUrl":"https://doi.org/10.1080/21645515.2024.2440164","url":null,"abstract":"People in Australia have access to different influenza vaccines, but may be unaware of their options and features. Preference studies for differentiated influenza vaccines including cell-based vaccines are limited, particularly in Australia. This study investigated which influenza vaccine attributes people in Australia value using a discrete choice experiment (DCE). Adults in Australia ineligible for free influenza vaccines had been vaccinated in the last 5 years and intended to be vaccinated again completed an online survey. Participants (N = 1203) were presented three influenza vaccine profiles described by eight attributes. Half the DCE scenarios described influenza season severity to be the same as last year, and the other half as more severe. DCE data were analyzed using a mixed multinomial logit (MMNL) model. All eight attributes significantly predicted vaccine choice (p < .05). Regardless of influenza season severity, participants preferred a vaccine: with greater protection, designed to be an exact match to circulating strains (match), using modern technology, manufactured by an Australian company, available at pharmacies, preferred by health care professionals (HCP), government funded for high-risk individuals and having lower cost. The top three attributes by importance were protection, match and cost. Participants were willing to pay more for match and higher protection. The Marginal Willingness to Pay (MWTP) for the most important attributes, excluding cost, were AUD $1.61/$2.18 for each additional percent in protection (same/more severe season), AUD $25.37/$32.37 for match and AUD $4.06/$15.97 for HCP preference. Findings indicate that match, protection, cost and HCP preference are key to vaccine choice, highlighting the importance of shared decision-making.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2440164"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acceptance and attitudes towards COVID-19 vaccination during pregnancy in Canada. 加拿大孕妇对接种 COVID-19 疫苗的接受程度和态度。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-02-03 DOI: 10.1080/21645515.2025.2458353

Suraya Bondy, Elisabeth McClymont, Gal Av-Gay, Arianne Albert, Janice Andrade, Sandra Blitz, Ianna Folkes, Lucia Forward, Erin Fraser, Sela Grays, Jon Barrett, Julie Bettinger, Tali Bogler, Isabelle Boucoiran, Eliana Castillo, Rohan D'Souza, Darine El-Chaâr, Shaza Fadel, Verena Kuret, Gina S Ogilvie, Vanessa Poliquin, Manish Sadarangani, Heather Scott, John W Snelgrove, Modupe Tunde-Byass, Deborah Money

{"title":"Acceptance and attitudes towards COVID-19 vaccination during pregnancy in Canada.","authors":"Suraya Bondy, Elisabeth McClymont, Gal Av-Gay, Arianne Albert, Janice Andrade, Sandra Blitz, Ianna Folkes, Lucia Forward, Erin Fraser, Sela Grays, Jon Barrett, Julie Bettinger, Tali Bogler, Isabelle Boucoiran, Eliana Castillo, Rohan D'Souza, Darine El-Chaâr, Shaza Fadel, Verena Kuret, Gina S Ogilvie, Vanessa Poliquin, Manish Sadarangani, Heather Scott, John W Snelgrove, Modupe Tunde-Byass, Deborah Money","doi":"10.1080/21645515.2025.2458353","DOIUrl":"10.1080/21645515.2025.2458353","url":null,"abstract":"The COVID-19 pandemic posed a unique set of risks to pregnant women and pregnant people. SARS-CoV-2 infection in pregnancy is associated with increased risk of severe illness and adverse perinatal outcomes. However, evidence regarding the use of COVID-19 vaccines in pregnancy shows safety and efficacy. Despite eligibility and recommendations for COVID-19 vaccination among pregnant women and pregnant people in Canada, uptake remains lower compared to the general population, warranting exploration of influencing factors. The COVERED study, a national prospective cohort, utilized web-based surveys to collect data from pregnant women and pregnant people across Canada on COVID-19 vaccine attitudes, uptake, and hesitancy factors from July 2021 to December 2023. Survey questions were informed by validated tools including the WHO Vaccine Hesitancy Scale (VHS) and the Theory of Planned Behavior (TPB). Of 1093 respondents who were pregnant at the time of the survey, 87.7% received or intended to receive a COVID-19 vaccine during pregnancy. TPB variables such as positive attitudes toward COVID-19 vaccines (OR = 1.11, 95% CI = 1.08-1.14), direct social norms, and indirect social norms were significantly associated with vaccine acceptance. Perceived vaccine risks, assessed by the WHO VHS, were greater in those not accepting of the vaccine. Our study identified several key factors that play a role in vaccine uptake: perceived vaccine risks and safety and social norms. These findings may guide public health recommendations and prenatal vaccine counseling strategies.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2458353"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792807/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stability study of recombinant 9-valent human papillomavirus vaccine based on Escherichia coli expression system.

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-02-20 DOI: 10.1080/21645515.2025.2455807

Yuying Liu, Dan Chen, Li Zhao, Haijiang Zhang, Shuming Wu, Xiao Chen, Ercui Shen, Ling Li, Zengmin Yang, Yan Wang, Fei Yin, Yao Zhang, Yazheng Shi, Shuyi Zhou, Shuang Li, Xiaoli Du, Jiaping Guo, Di Wang, Huan Wang, Shujuan Liu, Guiying Jin, Hongcai Zhang, Xinyu Yu, Xuejiao Chen, Lulu Shang, Yang Liu, Yongjiang Liu

{"title":"Stability study of recombinant 9-valent human papillomavirus vaccine based on Escherichia coli expression system.","authors":"Yuying Liu, Dan Chen, Li Zhao, Haijiang Zhang, Shuming Wu, Xiao Chen, Ercui Shen, Ling Li, Zengmin Yang, Yan Wang, Fei Yin, Yao Zhang, Yazheng Shi, Shuyi Zhou, Shuang Li, Xiaoli Du, Jiaping Guo, Di Wang, Huan Wang, Shujuan Liu, Guiying Jin, Hongcai Zhang, Xinyu Yu, Xuejiao Chen, Lulu Shang, Yang Liu, Yongjiang Liu","doi":"10.1080/21645515.2025.2455807","DOIUrl":"10.1080/21645515.2025.2455807","url":null,"abstract":"This study reports on the long-term stability of a recombinant 9-valent HPV vaccine, addressing a gap in the literature as previous research did not extend beyond 72 months. The vaccine targets HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 and was produced using an E. coli expression system. We optimized soluble HPV L1 protein expression by truncating the N- and C-termini, resulting in HPV L1 virus-like particles (VLPs). Structural analysis confirmed the VLPs' resemblance to natural ones, suitable for vaccine production. Stability testing encompassed appearance, dosage, pH, osmolarity, aluminum content, polysorbate 80, in vitro relative potency, abnormal toxicity, in vivo potency, sterility, and endotoxin levels. The vaccine showed stability under extreme conditions of light (4500 lx) and shaking table vibration (10-30 rpm) for at least 7 days at 5 ± 3°C. Long-term storage at 5 ± 3°C maintained stability for up to 72 months, while accelerated testing at 25 ± 2°C showed stability for at least 12 months. The findings suggest that the vaccine's potency is best preserved under protection from high temperatures and direct light, with even harsh conditions not significantly compromising stability. This enhances the global distribution potential of the HPV vaccine.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2455807"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11845052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143460134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0